| Reactivity | MuSpecies Glossary |
| Applications | WB, IHC |
| Clonality | Polyclonal |
| Host | Sheep |
| Conjugate | Alexa Fluor 405 |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse ErbB2/Her2 Thr23-Thr653 Accession # P70424 |
| Specificity | Detects mouse ErbB2/Her2 in direct ELISAs and Western blots. In Western blots using recombinant protein, approximately 10% cross‑reactivity with recombinant human ErbB2 is observed and less than 1% cross‑reactivity with recombinant mouse (rm) Er |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Sheep |
| Purity Statement | Antigen Affinity-purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Storage | Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied |
| Buffer | Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide |
ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a 185 kDa type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors for EGF superfamily growth factors. ErbB2 is widely expressed in epithelial cells and plays roles in development, cancer, communication at the neuromuscular junction, and regulation of cell growth and differentiation. The mouse ErbB2 extracellular domain (amino acids 23-653 of 1256) shares 85% and 94% aa identity with human and rat ErbB2 ECD, respectively. The protease ADAM10 releases a 110 kDa soluble fragment of ErbB2 from the cell surface. ErbB2 has no identified ligands, but heterodimerizes with ErbB1 (EGF R), ErbB3, or ErbB4 to form higher affinity signaling complexes. The ErbB2/ErbB3 heterodimer is expressed in the majority of breast, skin, ovary and gastrointestinal tumors and transduces a highly mitogenic signal in response to neuregulin 1 (NRG1; heuregulin 1) or NRG2.
Secondary Antibodies |
Isotype Controls |
|
Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach... Read full blog post. |
|
NPC1: A Potential Target For Triple-Negative Breast Cancer By Natalia Gurule, PhD Breast Cancer is a Heterogeneous DiseaseBreast cancer is the most frequently identified malignancy in women, accounting for 30% of diagnosed cases of cancer in women in the US annuall... Read full blog post. |
|
Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy By Victoria Osinski, PhDDespite advances in the development of cancer immunotherapies, those specifically targeting tumors still remains limited. Currently, there is great interest in utilizing chimeric antigen rece... Read full blog post. |
|
Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.